share_log

Medicenna Announces Appointment of New Auditor

Medicenna Announces Appointment of New Auditor

Medicenna 宣佈任命新核數師
GlobeNewswire ·  01/13 06:36

TORONTO and HOUSTON, Jan. 12, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX: MDNA, OTC: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, today announced the appointment of MNP LLP ("MNP" or "Successor Auditor") as auditor. The board of directors of the Company accepted the resignation of PricewaterhouseCooper LLP (the "Former Auditor") and appointed MNP as the new auditor until the next annual general meeting of shareholders of the Company.

多倫多和休斯頓,2024年1月12日(環球新聞專線)——專注於開發Superkines的臨床階段免疫療法公司Medicenna Therapeutics Corp.(“MDNA” 或 “公司”)(多倫多證券交易所股票代碼:MDNA,場外交易代碼:MDNAF)今天宣佈任命MNP LL(“MNP” 或 “繼任核數師”)爲核數師。公司董事會接受了普華永道會計師事務所(“前核數師”)的辭職,並任命MNP爲新核數師,直至公司下屆年度股東大會。

The Company confirms that there have been no reservations or modified opinions in the Former Auditor's report for the two most recently completed financial years or for any period subsequent to the most recently completed period for which an audit report was issued. The Company's board of directors and audit committee each approved the resignation of the Former Auditor and the appointment of MNP. There were no "reportable events", as the term is defined in National Instrument 51-102 – Continuous Disclosure Obligations ("NI 51-102"), in connection with each of the Former Auditor's audits of the Company which occurred prior to its resignation as auditor of the Company; and the required notices of change of auditor (the "Notices") were approved by the Company's board of directors.

公司確認,對於最近完成的兩個財政年度或最近結束的審計報告期之後的任何時期,前核數師的報告中沒有任何保留意見或修改意見。公司董事會和審計委員會分別批准了前核數師的辭職和MNP的任命。沒有 “應報告的事件”,正如國家儀器51-102中定義的那樣— 持續披露義務 (“NI 51-102”),涉及前核數師在辭去公司核數師職務之前對公司的每項審計;所需的核數師變更通知(“通知”)已獲得公司董事會的批准。

In accordance with NI 51-102, the Notices, together with the required letters from the Former Auditor and MNP, have been reviewed by the audit committee and the board of directors and have been filed on SEDAR+.

根據NI 51-102,通知以及前核數師和MNP的必要信函已經過審計委員會和董事會的審查,並已在SEDAR+上提交。

In addition, Medicenna has engaged Tandem Accounting Group Ltd. ("Tandem") to manage the Company's financial reporting and internal bookkeeping requirements on a contract basis. The Tandem team is co-led by Sean Hodgins, CPA, CPA (Illinois) and David Hyman, CPA, CBV. Mr. Hodgins was the founding CFO of Medicenna and is the current contract CFO of several public Canadian companies. Mr. Hodgins is the founder of Tandem and brings a wealth of public company reporting experience to the Company. Mr. Hyman is a seasoned financial professional with over 25 years of broad financial experience which includes public practice, capital markets, private equity, and CFO positions in both public and private companies in Canada.

此外,Medicenna已聘請Tandem會計集團有限公司(“Tandem”)以合同爲基礎管理公司的財務報告和內部簿記需求。Tandem團隊由註冊會計師、註冊會計師(伊利諾伊州)的肖恩·霍金斯和CBV註冊會計師大衛·海曼共同領導。霍金斯先生曾是Medicenna的創始首席財務官,目前是幾家加拿大上市公司的合同首席財務官。霍金斯先生是Tandem的創始人,爲公司帶來了豐富的上市公司報告經驗。海曼先生是一位經驗豐富的金融專業人士,擁有超過25年的豐富財務經驗,包括公共執業、資本市場、私募股權以及加拿大上市和私營公司的首席財務官職位。

About Medicenna

關於 Medicenna

Medicenna is a clinical-stage immunotherapy company focused on developing novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first-in-class empowered superkines. Medicenna's long-acting IL-2 Superkine, MDNA11, is a next-generation IL-2 with superior affinity toward CD122 (IL-2 receptor beta) with no CD25 (IL-2 receptor alpha) binding, thereby preferentially stimulating cancer-killing effector T cells and NK cells. Medicenna's IL-4 Empowered Superkine, bizaxofusp (formerly MDNA55), has been studied in 5 clinical trials enrolling over 130 patients, including a Phase 2b trial for recurrent GBM, the most common and uniformly fatal form of brain cancer. Bizaxofusp has obtained FastTrack and Orphan Drug status from the FDA and FDA/EMA, respectively. Medicenna's early-stage BiSKITs (Bifunctional SuperKine ImmunoTherapies) and the T-MASK (Targeted Metalloprotease Activated SuperKine) programs are designed to enhance the ability of Superkines to treat immunologically "cold" tumors.

Medicenna是一家臨床階段的免疫療法公司,專注於開發新型、高選擇性的IL-2、IL-4和 IL-13 Superkines以及同類首創的強化超因子。Medicenna 的長效 IL-2 Superkine MDNA11 是下一代白細胞介素-2,對沒有 CD25(IL-2 受體 α)結合的 CD122(IL-2 受體 β)具有優異的親和力,因此優先刺激殺癌效應 T 細胞和 NK 細胞。Medicenna的IL-4 Empowered Superkine bizaxofusp(前身爲 MDNA55)已在5項臨床試驗中進行了研究,招募了130多名患者,其中包括一項針對複發性GBM(最常見和最均勻致命的腦癌)的2b期試驗。Bizaxofusp已分別獲得美國食品藥品管理局和美國食品藥品管理局的FastTrack和Orphan Drug認證。Medicenna的早期BISKIT(雙功能SuperKine免疫療法)和T-MASK(靶向金屬蛋白酶活化SuperKine)計劃旨在增強Superkines治療免疫學 “冷” 腫瘤的能力。

For more information, please visit , and follow us on Twitter and LinkedIn.

欲了解更多信息,請訪問 Twitter 和 LinkedIn,並關注我們。

Forward-Looking Statements

前瞻性陳述

This news release contains forward-looking statements within the meaning of applicable securities laws that relate to the future operations of the Company, plans and projections and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expect", "believe", "seek", "potentially" and similar expressions and are subject to risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the risks detailed in the latest Annual Report on Form 20-F of the Company and in other filings made by the Company with the applicable securities regulators from time to time.

本新聞稿包含適用證券法所指的前瞻性陳述,這些陳述與公司未來運營、計劃和預測以及其他非歷史事實的陳述。前瞻性陳述通常以 “將”、“可能”、“應該”、“預期”、“期望”、“相信”、“尋求”、“潛在” 等術語和類似表述來識別,並受風險和不確定性的影響。無法保證此類陳述會被證明是準確的,實際結果和未來事件可能與此類聲明中的預期有重大差異。可能導致實際業績與公司預期存在重大差異的重要因素包括公司最新的20-F表年度報告以及公司不時向相關證券監管機構提交的其他文件中詳述的風險。

The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date hereof and except as required by law, we do not intend and do not assume any obligation to update or revise publicly any of the included forward-looking statements.

提醒讀者,在準備任何前瞻性信息時使用的假設都可能被證明是不正確的。由於許多已知和未知的風險、不確定性和其他因素,其中許多是公司無法控制的,事件或情況可能導致實際業績與預測存在重大差異。提醒讀者不要過分依賴任何前瞻性信息。儘管管理層認爲此類信息是合理的,但可能被證明是不正確的,實際結果可能與預期有重大差異。本新聞稿中包含的前瞻性陳述受本警示聲明的明確限制。本新聞稿中包含的前瞻性陳述自發布之日起作出,除非法律要求,否則我們無意也不承擔任何義務公開更新或修改所包含的任何前瞻性陳述。

Investor and Media Contacts

投資者和媒體聯繫人

Christina Cameron
Investor Relations, Medicenna Therapeutics
ir@medicenna.com

克里斯蒂娜卡梅隆
投資者關係,Medicenna Therapeutics
ir@medicenna.com

Investor Contact
Argot Partners
Phone: 212-600-1902
medicenna@argotpartners.com

投資者聯繫人
Argot Par
電話:212-600-1902
medicenna@argotpartners.com


譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論